As Biodesix continues clinical validation and commercialization of its test to predict patient response to therapies for non-small cell lung cancer, it is looking to forge pharmaceutical partnerships to increase adoption of the test. The company is in the midst of conducting a trial in Italy to determine whether the test can determine which NSCLC patients may respond best to treatment with EGFR inhibitors such as erlotinib versus other therapies such as docetaxel. It hopes to release data from the trial at the annual meeting of the American Society of Clinical Oncology in 2012.
While that is happening, the Broomfield, Colo.-based firm is increasing efforts targeting drug firms as part of its strategy to build up commercialization of the proteomic test, Biodesix’s vice president of business development and strategic marketing, Paul Beresford, told GenomeWeb Daily News during the JP Morgan Healthcare Conference last week. (Read more at GenomeWeb)